Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 8/20 | 0.50 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.48 |
| ▸ | JAK3 | P52333 | 3/20 | 0.39 |
| ▸ | JAK1 | P23458 | 1/20 | 0.39 |
| ▸ | CDC7 | O00311 | 1/20 | 0.39 |
| ▸ | CDK2 | P24941 | 1/20 | 0.39 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.35 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.35 |
| ▸ | PDE8A | O60658 | 1/20 | 0.35 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.34 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.34 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.34 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.34 |
| ▸ | MTOR | P42345 | 2/20 | 0.34 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2273140 | 0.77 | CDC7 (0.40) | CDC7CDK2PDCD1CD274MAPK14 | |
| Hydrochloric Acid SCHEMBL16553729 | 0.76 | JAK2 (0.50) | JAK2NUDT1JAK3JAK1 | |
| SCHEMBL16554303 | 0.76 | JAK2 (0.50) | JAK2NUDT1JAK3JAK1 | |
| SCHEMBL19220944 | 0.75 | JAK2 (0.49) | JAK2NUDT1JAK3JAK1 | |
| SCHEMBL12079212 | 0.75 | JAK2 (0.52) | JAK2NUDT1JAK3JAK1 | |
| SCHEMBL2270706 | 0.72 | JAK2 (0.50) | JAK2NUDT1JAK3JAK1 | |
| SCHEMBL18367046 | 0.69 | JAK2 (0.77) | JAK2NUDT1JAK3JAK1PTK2 | |
| SCHEMBL8786339 | 0.69 | ALDH1A1 (0.43) | CDC7CDK2PDCD1CD274MAPK14 | |
| SCHEMBL2252442 | 0.68 | PIK3CA (0.47) | JAK2NUDT1JAK3PIK3CAMTOR | |
| SCHEMBL16553842 | 0.68 | JAK1 (0.70) | JAK2JAK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2531503-A1 | GAMMA SECRETASE MODULATERS | F. Hoffmann-La Roche AG (CH) | 2012-12-12 | — | — | EP | disclosed |
| WO-2011092272-A1 | GAMMA SECRETASE MODULATERS | F. HOFFMANN-LA ROCHE AG (CH) | 2011-08-04 | — | — | WO | disclosed |
| US-20110190269-A1 | GAMMA SECRETASE MODULATORS | HOFFMANN-LA ROCHE, INC. | 2011-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110190269-A1 | GAMMA SECRETASE MODULATORS | BACE1, APH1A, APH1B | JAK2 4637/4885NUDT1 1834/4885JAK3 4543/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.